GNMX Aevi Genomic Medicine
5,508
| Market Cap | $0.00 |
| 52-Wk High | $0.00 |
| 52-Wk Low | $0.00 |
ST Data
Watchers
New Watcher Rank
Cerecor inks CERC-002 licensing deal with Kyowa Kirin, shares up 6%SeekingAlpha.com: All News • over 2 years ago
---
- Cerecor's (CERC) wholly-owned subsidiary, Aevi Genomic Medicine (GNMX) has entered
into an expanded agreement with Kyowa Kirin (KYKOF), for exclusive worldwide rights
to...
Share to Feed
---
- Aevi Genomic Medicine (NASDAQ:GNMX) and Amgen (NASDAQ:AMGN) are both medical companies,
but which is the better stock? We will contrast the two businesses based on the
strength of their analyst recommendations, valuation, risk, profitability, institutional
ownership, earnings and dividends. Insider ...
---
- Amgen (NASDAQ:AMGN) and Aevi Genomic Medicine (NASDAQ:GNMX) are both companies,
but which is the superior business? We will contrast the two businesses based on
the strength of their institutional ownership, analyst recommendations, earnings,
valuation, profitability, risk and dividends. Earnings ...
---
- Maryland biopharmaceutical company Cerecor has completed its acquisition of Wayne-based
Aevi Genomic Medicine Inc. in a transaction involving two companies both focused
on developing new therapies for rare pediatric diseases. The all-stock deal, first
disclosed in December, carries a value up to $22.1 million.
---
- Maryland biopharmaceutical company Cerecor has completed its acquisition of Wayne-based
Aevi Genomic Medicine Inc. in a transaction involving two companies both focused
on developing new therapies for rare pediatric diseases. The all-stock deal, first
disclosed in December, carries a value up to $22.1 million.
---
- Maryland biopharmaceutical company Cerecor has completed its acquisition of Wayne-based
Aevi Genomic Medicine Inc. in a transaction involving two companies both focused
on developing new therapies for rare pediatric diseases. The all-stock deal, first
disclosed in December, carries a value up to $22.1 million.
---
- "-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan
Diseases-Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief
Medical Officer ROCKVILLE, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:
CERC), a biopharmaceutical company focused on ..."
---
- 'Cerecor to Acquire Aevi Genomic Medicine Cerecor to Acquire Aevi Genomic Medicine
PR Newswire PHILADELPHIA, Dec. 5, 2019 PHILADELPHIA, Dec. 5, 2019 /PRNewswire/ --
Aevi Genomic Medicine, Inc. (''Aevi'') (Nasdaq: GNMX) today announced that it entered
into a definitive merger agreement with ...'
---
- "-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare
and Orphan Diseases-Enhances Leadership Team with the Addition of Chief Executive
Officer and Chief Medical Officer-Strategic Alternatives Being Explored for Neurological
Assets and Millipred ROCKVILLE, Md., Dec. 05, ..."
---
- Aevi Genomic Medicine Inc (NASDAQ:GNMX) has earned a consensus broker rating score
of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks
Investment Research reports. One investment analyst has rated the stock with a hold
rating. Analysts have set a 1 year consensus price ...
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.
Latest GNMX News
Cerecor inks CERC-002 licensing deal with Kyowa Kirin, shares up 6%
SeekingAlpha.com: All News • over 2 years ago
Contrasting Aevi Genomic Medicine (NASDAQ:GNMX) & Amgen (NASDAQ:AMGN)
Ticker Report • almost 4 years ago
Head-To-Head Comparison: Amgen (NASDAQ:AMGN) & Aevi Genomic Medicine (NASDAQ:GNMX)
Zolmax • almost 4 years ago